臨牀透析 Vol.29 No.13(2-2)


特集名 腎性貧血治療の新たな課題―ESA低反応性と鉄代謝異常
題名 鉄代謝 (2) 慢性腎臓病における鉄代謝異常
発刊年月 2013年 12月
著者 中西 健 兵庫医科大学内科学腎・透析科
著者 名波 正義 兵庫医科大学内科学腎・透析科
著者 蓮池 由起子 兵庫医科大学内科学腎・透析科
【 要旨 】 われわれは,以前より血液透析患者の予後に重大な影響を及ぼすと考えられる感染症や心血管事象の発症に,鉄の調節・輸送異常が関与するとの仮説をもとに研究を進めてきた.細胞内外で見てみると,細胞から鉄を汲み出す蛋白であるフェロポーチンの発現を調節する炎症性サイトカインや鉄調節ホルモンであるヘプシジンが増加し細胞の中に“鉄の囲い込み”が起こる.細胞内鉄代謝では,ミトコンドリアにおいて鉄を保持し,鉄―硫黄クラスターを維持する作用のあるフラタキシン,エンドソームから鉄を汲み出しミトコンドリアに供給していると考えられるNramp1のいずれもが低下することにより細胞内鉄配置異常が起こる.このように,鉄代謝の多くのステップにおける異常を介して合併症に関連している可能性が示唆された.
Theme Problems to be solved in the therapy for renal anemia : Association of ESA hyporesponsiveness with dysregulated iron metabolism
Title Dysregulated iron metabolism in chronic kidney disease
Author Takeshi Nakanishi Division of Kidney and Dialysis, Department of Internal Medicine, Hyogo College of Medicine
Author Masayoshi Nanami Division of Kidney and Dialysis, Department of Internal Medicine, Hyogo College of Medicine
Author Yukiko Hasuike Division of Kidney and Dialysis, Department of Internal Medicine, Hyogo College of Medicine
[ Summary ] We hypothesize that dysregulation of iron metabolism may be associated with infectious diseases and cardiovascular events which are the leading causes of mortality in patients on maintenance hemodialysis (MHD). Iron transport between intracellular and extracelluar regions, inflammatory cytokines and hepcidin, which may decrease the expression of the iron export protein, ferroportin have all been demonstrated to increase in these patients. This may cause iron sequestration in various types of cells. Intracellular iron metabolism is due to the mitochondrial iron-binding protein, frataxin. It can act as an iron chaperone protein and reduce the formation of Fe-sulfur cluster proteins which are lowered in MHD patients. The downregulation of frataxin is linked to hypercytokinemia and oxidative stress. Iron transport protein in endosomes, Nramp1, which can export iron from phagosomes/lysosomes, is downregulated. The decrease in Nramp1 causes iron retention in phagosomes, facilitates growth of intracellular pathogens and also hampers the handling of iron directed to mitochondria. From these observations, we can presume that the misregulation of iron metabolism and the mislocalization of iron in the cells may cause varioius complications via oxidative stress in MHD patients.
戻る